Dr. Niklas Klümper
Department of Urology and Institute of Experimental Oncology
niklas.kluemper@ukbonn.de View member: Dr. Niklas Klümper
European urology
Accumulating data support nectin-4, particularly membranous expression, as a predictive biomarker of enfortumab vedotin activity. Low expression identifies patients with poorer outcomes but not absence of benefit, underscoring the need for standardized prospective validation before clinical implementation.
Copyright © 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PMID: 42829269